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Summary
 Background The topic of this study was lobular carcinoma, the second most frequently diag-
nosed cancer of the breast, which is less well known and is more problematic, di-
agnostically.
 Aim To deﬁ ne a prognostic index for patients with lobular carcinoma of the breast 
through application of a multivariate analysis, Cox’s proportional hazard model.
 Materials/Methods An immunohistochemistry based analysis was carried out on parafﬁ n embedded 
materials taken from 75 women who underwent surgery for lobular carcinoma of 
the breast in the Oncological Surgery Department, Poznań University of Medical 
Sciences, during the period of 1990–1997.
 Results A statistically signiﬁ cant relationship was found between the size of tumour 
(p=0.044), lymph node status (p=0.011), expression of progesterone receptors 
(p=0.034), and survival time. In support of the above parameters, the multivari-
ate analysis allowed the formulation of a prognostic index: I=T+2N-2PgR, where 
T (tumour)=tumour size, N (nodulus)=lymph node status, and PgR=expression 
of progesterone receptors.
 Conclusions The formulated prognostic index for lobular carcinoma of the breast allows for 
the differential prognosis of survival time, in representative risk groups. The in-
dex may be useful in the process of qualifying patients for adjuvant therapy.
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BACKGROUND
The most common cause of death among patients 
treated radically for breast cancer is progression of 
the disease, by metastasis, to remote sites. Effective 
treatment of breast cancer must take the form of 
combined therapy. Qualiﬁ cation for treatment de-
pends on the stage of disease and on the analysis 
of prognostic factors (which allow for a prognosis 
to be made, regardless of treatment method) and 
predictive factors (which allow us to foresee the 
effectiveness of applied therapies) [1–8].
The topic of interest for these authors is lobular 
carcinoma (carcinoma lobulare), which is the 
second most frequently diagnosed cancer of the 
breast, after ductal carcinoma. Invasive lobular 
carcinoma accounts for 5–20% of all breast can-
cer diagnoses. It is often diagnosed multifocal-
ly or bilaterally and is diagnostically problemat-
ic. Frequently it is “silent” in mammography. It 
is also difﬁ cult to assess cytologically, a result of 
its structure. In their classic form, lobular carci-
noma cells are scattered singularly or form bar-
rel shaped clusters, sometimes arranged con-
centrically. These cells are small, round and 
regular, with scanty cytoplasm. The number of 
nuclear polymorphisms is low and ﬁ gures are 
of a low scale. Stroma is usually scant and glassy. 
Inﬁ ltration of lymphocytes and plasma cells is 
seen less frequently than in other forms of can-
cer of the breast [9–12].
In the case of lobular carcinoma, completion and 
modiﬁ cation of the histological staging of malig-
nancy, according to Elston and Ellis, requires the 
grading of three morphological factors: duct for-
mation, nuclear polymorphism of cells and the 
number of mitoses [13,14].
AIM
The purpose of the study was to deﬁ ne a prog-
nostic index for patients diagnosed with lobu-
lar carcinoma of the breast, using patho-clinical 
prognostic parameters and immunohistochem-
ical markers veriﬁ ed earlier.
MATERIALS
An immunohistochemical analysis was performed 
on materials derived from 75 women, aged from 
31 to 84, treated for lobular carcinoma of the 
breast in the Oncological Surgery Department, 
Poznań University of Medical Sciences, in the 
years 1990–1997.
METHODS
Clinical information was obtained from docu-
ments in the Oncology Department of Poznań 
University of Medical Sciences. In the case of pa-
tients who died outside the hospital, the date and 
cause of death were obtained from the Register of 
Malignant Cancers in the Statistics Department of 
the Great Poland Cancer Centre in Poznań.
The results of microscopic studies were obtained 
thanks to the Department of Histopathology, 
Poznań University of Medical Sciences, where 
slides were reassessed, veriﬁ ed and graded, with 
regard to the histological stage of malignancy, 
according to the Elston scale.
Immunohistochemical tests, using selected mark-
ers, were undertaken in the laboratory of the 
Department of Histopathology.
Nuclear staining reactions were graded for oes-
trogen receptors (ER), progesterone receptors 
(PgR), p53 and Ki67. Cytoplasmic reactions 
were graded for cathepsin D (CD) and MMP-
2. Reactions in the cell membranes were grad-
ed for HER-2.
The characteristics of the group studied and the 
results of immunohistochemical tests are present-
ed in Table 1.
A curve showing overall survival was produced 
using the Kaplan-Meier method. In order to de-
termine relationships between selected factors, 
we applied Cox’s non-parametric proportional 
hazard regression model.
Useful patho-clinical factors and immunohistochem-
ical markers for lobular carcinoma of the breast have 
been presented in earlier publications [15].
RESULTS
After completion of the multi-factor statistical 
analysis, signiﬁ cant prognostic factors are: tumour 
size (p=0.044), the presence of metastases to the 
axillary lymph nodes (p=0.011) and expression 
of progesterone receptors (p=0.034). The results 
of the multi-factor analysis are shown in Table 2. 
The survival curve for patients in our study group 
is shown in Figure 1.
Based on the parameters of the multi-factor analy-
sis used, the prognostic index was calculated ac-
cording to the following formula:
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I = b × z + b × z + b x z +....,
where b = factor, and z = marker.
The index is I = 0.7 × T + 1.5 × N + (–1.5) × PgR.
Taking into consideration the standard deviation, 
the Cox index was normalised by dividing the sides 
by 0.8, in order to make the factors into integers.
The ﬁ nal formula for the Cox Index is:
I = T + 2N – 2PgR,
where T (tumour) = tumour size, N (nodulus) = 
lymph node status, and PgR = expression of pro-
gesterone receptors.
In order to differentiate risk groups, it was neces-
sary to re-write the values of certain parameters. 
For tumour sizes (T) less than 2 cm we recorded 
a score of 1, for medium sized tumours from 2 to 
5 cm we scored 2, and for tumours larger than 
5 cm a score of 3 was recorded. For lymph node 
status (N) we recorded a score of 0 where no me-
tastasis was found, while a score of 1 was noted if 
metastasis was detected. In cases where expres-
sion of progesterone receptors was not seen, a 
score of 0 was noted while a score of 1 denoted 
that expression of progesterone receptors had 
been detected. The analyzed group of patients, 
with lobular carcinoma of the breast, was divid-
ed into three categories, with regard to their risk 
of relapse and death. Qualiﬁ cation for these risk 
groups was based on the following criteria.
Group 1 included patients in the lowest risk cat-
egory. Qualiﬁ cation for inclusion in this group 
was as follows:
•  diameter of tumour less than 5 cm (T:1 and 2),
•  no metastases to the axillary lymph nodes de-
tected (N:0),
•  expression of progesterone receptors demon-
strated (PgR:1).
Such values were accepted and used in possible 
combinations for the previously formulated Cox 
Index. It was found that in the low risk group, 
the prognostic index is: – 1 or 0.
Patients in the group most at risk of relapse were 
classiﬁ ed into group 3 as follows: 
•  metastases to the axillary lymph nodes detect-
ed (N:1),
•  expression of progesterone receptors could not 
be demonstrated (PgR:0)
Characteristic Number %
Total Number of Patients  75  100
Average age 56.9
years (age range) (31–84)
Standard deviation  13.42
Hormonal status
Premenopausal  30  40.0
Postmenopausal  45  60.0
Deaths during observation period  21  28.0
Observation period (months) – median  105.9
Size of tumour
   T 1  18  24.0
   T 2  43  57.3
   T 3  8  10.7
   T 4  6  8.0
Lymph node status
   N 0  16  21.3
   N 1  56  74.7
   N 2  3  4.0
  p N 1  32  42.7
Histological grade of malignancy 
according to the Elston scale
   G 1  12  16.0
   G 2  47  62.7
   G 3  7  9.3
no data  9  12.0
Markers
   ER (+)  53  72.6
   PgR (+)  61  82.4
   CD (+)  49  73.1
   p53 (+)  20  29.4
   Ki 67 (+)  46  71.9
   MMP-2 (+)  37  57.8
   HER-2 (+3)  4  5.9
Table 1. Clinical and pathological characteristics of group.
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• irrespective of tumour size (T:1, 2 and 3).
After inserting the values accepted for the group 
into the formula, the prognostic index for the 
group was calculated and amounts to: 3, 4 and 5.
The remainder of the patients, who qualiﬁ ed for 
neither group 1 nor group 3, were deemed to be 
at medium risk and were categorized into group 
2. For such patients, the prognostic index was ei-
ther 1 or 2, depending on the data put into the 
Cox Index.
The qualiﬁ cation scheme described above is 
shown in Figure 2.
Table 3 shows a comparison of survival times for 
patients in the groups at low, medium and high 
risk of death. The most numerous group is group 
2 – the medium risk group – and is comprised of 
31 patients. In this group, 10 deaths were record-
ed during the observation period, giving a 32.3% 
risk of death. The second largest group was group 
1 – the low risk category. 28 patients qualiﬁ ed for 
this group, among whom 2 deaths were recorded. 
Based on this, the likelihood of death in the low 
risk group may be set at 7.1%. Into group 3 – the 
high risk group – we classiﬁ ed 16 cases and the risk 
of death was signiﬁ cantly higher – 56.3%. Figure 3 
shows a graphical representation of the chances for 
survival in each of the risk groups. Differentiation 
of the course of disease in cases of good, poor or 
medium prognosis is clearly needed.
DISCUSSION
In spite of the diagnostic difﬁ culties, which of-
ten include such risks as multi-focal changes, bi-
lateral and sometimes disseminated disease, lob-
ular carcinoma can have a better prognosis than 
ductal carcinoma – the most common cancer of 
the breast. This can be proved by the fact that 
the third degree of histological malignancy, G3, 
Statistical analysis of survival
Dependency: survival – calculated in months taking into consideration the incomplete observations 
Size of group 75, incomplete: 54, complete: 21
Chi2=25,8689; df=12; p=0.01123 (p<0.05)
Prognostic factor Beta Standard deviation Exponent beta (risk factor) p
Age of patient  0.052  0.042467  1.053683
Hormonal status  –2.013  1.105447  0.133636
Size of tumour T  0.799  0.396986  2.223897 p<0.05
Metastases to lymph nodes N  1.536  0.606240  4.646432 p<0.05
Grading G  –0.697  0.675556  0.498074
ER  0.789  0.822221  2.200582
PgR  –1.511  0.716318  0.220671 p<0.05
CD  0.610  0.878251  1.840912
p 53  0.626  0.751286  1.870675
Ki 67  0.121  0.739315  1.128056
MMP-2  –0.049  0.619147  0.952548
HER-2  –0.474  0.637646  0.622719
Table 2. Correlation between examined factors and overall survival using the Cox proportional hazards regression model of survival.
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Figure 1. Kaplan-Meier’s accumulated survival rates for patients 
with invasive lobular breast cancer.
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is rarely diagnosed in lobular carcinoma and by 
the more common ﬁ nding of expression of ER 
and PgR, and the over-expression of HER-2, also 
by the lower percentage of deaths within the ob-
servation period. Other authors have also reached 
the conclusion that lobular carcinoma has a bet-
ter prognosis [5,7,16–22]. Jeziorski found that 
lobular carcinoma with metastasis to the lymph 
nodes is associated with longer periods free from 
relapse and overall survival than is the case in 
ductal carcinoma [23]. Furthermore, in a study 
carried out by Ishige et al. it was found that the 
presence of a lobular component in ductal car-
cinoma is associated with a better prognosis. The 
investigators concluded that the presence of lob-
ular structures could be a new prognostic factor 
for ductal carcinoma [24].
The classiﬁ cation of patients into groups of cas-
es with good, medium and poor prognosis is a 
I = T + 2N _ 2PgR
T
<2 cm _ 1
2_5 cm _ 2
>5 cm _ 3
N
N 0 _ 0
N 1 _ 1
PgR
PgR(_) _ 0
PgR(+) _ 1
GROUP 1
low risk group
T: N1_2
N: 0
PgR: 1
GROUP 2
high risk group
T: N1_3
N: 1
PgR: 0
GROUP 3
medium risk group
T: 
N: 
PgR: 
Remainder of
cases (other
than groups 1
and 3}
I = _1, 0 I = 3, 4, 5 I = 1, 2
.
Figure 2. Value of prognostic index in each risk group, applying the Cox formula.
Descriptive statistics for each group
Group Median Mean Standard deviation Number of deaths in group
Number of cases 
in group
1. 67.5 59.35714 32.98733 2 28
2. 68.0 61.64516 32.55308 10 31
3. 36.5 41.68750 33.49969 9 16
Totals 65.0 56.53333 33.40267 21 75
Table 3. Comparison of survival in low, medium and high risk groups.
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matter of the greatest importance for the prop-
er and appropriate planning of patients’ treat-
ment. Sundquist and co-workers assert that the 
Nottingham Prognostic Index allows us to use 
more exact prognostic data than lymph node sta-
tus alone – the strongest prognostic factor [25]. 
Baker et al. suppose that different prognostic fac-
tors are of value at each stage in the process of 
advancement of the neoplasm [26].
In practical oncology, most helpful indices are: 
The Nottingham Prognostic Index (which in-
cludes the size of the tumour, lymph node sta-
tus and histological degree of malignancy accord-
ing to the Bloom-Richardson scale) and the Van 
Nuys Index (which supports the treatment of duc-
tal carcinoma in situ) [25,27–32]. Also cited in 
the literature is the Adelaide Prognostic Index, 
in which the diameter of the neoplasm, expres-
sion of progesterone receptors and cellular pro-
liferation potential are graded [2].
Our second aim was to deﬁ ne the special prog-
nostic index for lobular carcinoma. After assess-
ing the independent diagnostic factors (T, N & 
PgR) in the observed group, they were used in 
a Cox Index in the following stage to create a 
prognostic index for lobular carcinoma of the 
breast. More importantly, it allows the deﬁ ni-
tion of qualifying criteria for individual risk 
groups. Patients with metastases to the lymph 
nodes and lacking expression of progesterone 
receptors can therefore be classiﬁ ed into the 
group with the worst prognosis. Qualiﬁ cation 
for this group does not require the size of the 
tumour to be taken into account which, bear-
ing in mind the biology of lobular carcinoma, 
is an obvious matter.
The group at the highest risk of death, in this 
study, was the smallest (21.3%), and the likeli-
hood of a 5-year survival amounted to nearly 43%. 
The next group was that of the best prognosis 
in cases of lobular carcinoma, into which we in-
cluded patients with tumours < 5 cm in diame-
ter, without metastases to the lymph nodes and 
who expressed PgR. This group accounted for 
37.3%. The largest group, that of medium risk, 
was only 4% larger. The likelihood of 5-year sur-
vival in the group with the best prognosis amount-
ed to nearly 93% while it only came close to 68% 
in the medium risk category.
In these days of dynamic growth in the ﬁ eld of 
genetic sciences we can predict that, after only 
a few years more, information regarding the 
course of disease may be obtained by an analy-
sis of the genetic proﬁ le. We already know that 
the “genetic signature” gives prognostic informa-
tion which is tens of times better than the con-
ventional prognostic factors we have been using 
up to the current time. Known groups of genes 
code for information regarding whether or not 
a tumour is likely to metastasize or not. It is also 
known that certain groups of genes control the 
route of metastasis, whether it be via the blood 
vessels or by the lymphatic system. Such an ap-
proach is revolutionising qualiﬁ cation for adju-
vant therapy [33,34].
The prognostic index we propose may be used to 
deﬁ ne the groups of patients at the highest risk 
of relapse or death in cases of lobular carcino-
ma. It allows a more precise qualiﬁ cation scheme 
for adjuvant therapy in the treatment of patients 
suffering from the second most commonly diag-
nosed cancer of the breast.
CONCLUSIONS
1.  The use of a multi-factor analysis, according to 
Cox’s proportional hazard method, allows the 
formulation of a prognostic index for lobular 
carcinoma of the breast.
2.  Application of the prognostic index allows for 
patients to be classiﬁ ed into risk groups such 
that differential prognosis and total survival 
time can be more accurately predicted.
3.  After further clinical testing in a larger group of 
patients, the prognostic index for lobular car-
Figure 3. Accumulated proportion of survivors – Kaplan-Meier 
method. Group 1: I=–1.0; Group 2: I=1.2; Group 3: I=3,4,5
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cinoma could be used in the process of quali-
fying patients for adjuvant therapy.
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